Article Text

PDF
PTU-098 Tace for hcc: long term outcome in a regional centre
  1. A Liaros1,
  2. J Deosaran1,
  3. A Ahmed1,
  4. M Priest2,
  5. S Barclay1,
  6. E Forrest1,
  7. R Gillespie1,
  8. J Evans3,
  9. J Graham3,
  10. D Kay2,
  11. R Kasthuri2,
  12. A Stanley1
  1. 1Glasgow Royal Infirmary
  2. 2Gartnavel General Hospital
  3. 3Beatson Oncology Unit, Glasgow, UK

Abstract

Introduction The incidence of hepatocellular carcinoma (HCC) is rising.1,2 Transarterial chemoembolisation (TACE) is frequently used as a palliative treatment or as a bridge to surgery. TACE can be offered alone, or together with radiofrequency ablation (RFA) or Sorafenib. Child-Pugh grade and Barcelona Clinic Liver Cancer Staging System (BCLC) are useful prognostic tools. Our aim was to assess outcome for patients receiving TACE over a 6 year period in our regional centre.

Method Patients with HCC were prospectively entered onto a regional HCC database between 01.01.09–01.01.15. Patients who underwent TACE (in addition to other therapies) were identified and clinical data obtained from electronic records. Child-Pugh grade and BCLC were calculated at time of diagnosis, with survival our primary outcome.

Results 497 patients were diagnosed with HCC during this period. 121 (99 male, 22 females; mean age 68 years) underwent TACE. 20, 47 and 54 patients had TACE during the periods 2009–10, 2011–12 and 2013–14 respectively. 102 (84%) had TACE alone, 6 (5%) each had TACE with RFA and TACE with Sorafenib, 5 (4%) had TACE then transplant, and two TACE then resection. 87 (72%), 31 (26%) and 3 (2%) had Child-Pugh grade A, B and C disease respectively and 38 (31%), 61 (50%), 20 (17%) and 2 (2%) BCLC stage A, B, C and D.

Of the 102 patients having TACE alone, survival is shown in table:

Two year survival for patients having TACE and RFA was 80%; for TACE and Sorafenib 17% and for TACE then transplant/resection 100%.

Conclusion There has been a steady rise in the number of patients with HCC undergoing TACE procedures in our unit. Survival following TACE compares favourably to other studies.3,4

References

  1. . Cancer Mortality in Scotland (2015). Information Services Division publication report. https://isdscotland.scot.nhs.uk/Health-Topics/Cancer/Publications/2016-10-25/2016-10-25-Cancer-Mortality-Report.pdf [Accessed 26/10/16].

  2. . Liver Cancer Incidence Trends Great Britain 1979-2013. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/liver-cancer/incidence#heading-Two [Accessed: 31/10/16].

  3. . EASL–EORTC clinical practice guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 201256: 908–943.

  4. . Greten T.F., Papendorf F., Bleck J.S., Kirschhoff T., Wohlberedt T., Kubicka S., Klempnauer J., Galanski M., Manns M.P. Survival rate in patients with hepatoceullar carcinoma: a retrospective analysis of 389 patients. British Journal of Cancer, 2005. 92: 1862–1868.

Disclosure of Interest None Declared

  • HEPATOCELLULAR CARCINOMA
  • SURVIVAL
  • TACE

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.